These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26412881)

  • 1. Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure.
    Ogawa H; Ajioka M; Ishii H; Okumura T; Murase Y; Osanai H; Nakasima Y; Asano H; Sakai K; Murohara T
    Nagoya J Med Sci; 2015 Aug; 77(3):355-62. PubMed ID: 26412881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation and long-term use of tolvaptan for patients with worsening heart failure through hospital and clinic cooperation.
    Uemura Y; Shibata R; Ishikawa S; Takemoto K; Murohara T; Watarai M
    Nagoya J Med Sci; 2021 Aug; 83(3):431-441. PubMed ID: 34552281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan.
    Takimura H; Hada T; Kawano M; Yabe T; Takimura Y; Nishio S; Nakano M; Tsukahara R; Muramatsu T
    PLoS One; 2018; 13(11):e0207481. PubMed ID: 30427915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Effects of Early and Short-Term Tolvaptan Administration in Patients Hospitalized for Acute Decompensated Heart Failure.
    Tanaka N; Dan K; Maeda T; Ishihara H; Teramura M; Ichihashi K; Takahashi Y; Tsuzura D; Shinoda A; Fujii M; Okada H; Teramoto T
    Cardiology; 2021; 146(6):739-747. PubMed ID: 34348260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.
    Vaduganathan M; Goldsmith SR; Senni M; Butler J; Gheorghiade M
    Eur J Heart Fail; 2016 Feb; 18(2):185-91. PubMed ID: 26443242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
    Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA
    Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
    Vaduganathan M; Gheorghiade M; Pang PS; Konstam MA; Zannad F; Swedberg K; Grinfeld L; Burnett JC; Krasa HB; Zimmer C; Blair J; Ouyang J; Maggioni AP;
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):415-22. PubMed ID: 22673023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    Int J Cardiol; 2016 Oct; 221():188-93. PubMed ID: 27404673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y
    Biomed Res Int; 2014; 2014():704289. PubMed ID: 25436213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    J Card Fail; 2016 Jun; 22(6):423-32. PubMed ID: 26915749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
    Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
    J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan.
    Kobayashi M; Hayashi M; Yamada R; Ishiguro T; Fujiwara W; Ishii H; Naruse H; Watanabe E; Ozaki Y; Izawa H
    Fujita Med J; 2023 May; 9(2):80-83. PubMed ID: 37234387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.